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Objectives The purpose of this study was to provide a systematic multicenter survey on the incidence and causes of death
occurring in the setting of or as a consequence of catheter ablation (CA) of atrial fibrillation (AF).
Background CA of AF is considered to be generally safe. However, serious complications, including death, have been reported.
Methods Using a retrospective case series, data relevant to the incidence and cause of intra- and post-procedural death
occurring in patients undergoing CA of AF between 1995 and 2006 were collected from 162 of 546 identified
centers worldwide.
Results Thirty-two deaths (0.98 per 1,000 patients) were reported during 45,115 procedures in 32,569 patients. Causes
of deaths included tamponade in 8 patients (1 later than 30 days), stroke in 5 patients (2 later than 30 days),
atrioesophageal fistula in 5 patients, and massive pneumonia in 2 patients. Myocardial infarction, intractable
torsades de pointes, septicemia, sudden respiratory arrest, extrapericardial pulmonary vein (PV) perforation,
occlusion of both lateral PVs, hemothorax, and anaphylaxis were reported to be responsible for 1 death each,
while asphyxia from tracheal compression secondary to subclavian hematoma, intracranial bleeding, acute
respiratory distress syndrome, and esophageal perforation from an intraoperative transesophageal echocardio-
graphic probe were causes of 1 late death each.
Conclusions Death is a complication of CA of AF, occurring in 1 of 1,000 patients. Knowledge of possible precipitating
causes is key to operators and needs to be considered during decision making with patients. (J Am Coll
Cardiol 2009;53:1798–803) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.02.022(
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ratheter ablation (CA) around the pulmonary vein (PV)
egion is increasingly used to treat atrial fibrillation (AF)
1–4). The procedure is generally effective and safe (5,6),
ut devastating complications may occasionally occur, some
f them ultimately leading to death of the patient (5,7).
ystematic assessment of death rates and precipitating
auses is difficult, because of the rare occurrence of death,
aking its description anecdotal in single-center reports
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ion (7). As a consequence, physicians performing CA of
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F sometimes discuss this complication, but a clear picture
bout its incidence in the real-world practice is lacking. Yet,
ortality data remain important and may serve as a guide to
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May 12, 2009:1798–803 Fatalities in Catheter Ablation of AFlinicians considering CA of AF. We provide a systematic
eport on the incidence and causes of death associated with
A of AF obtained in a large retrospective case series.
ethods
tudy design. Data relevant to determining the incidence
nd the precipitating causes of death were derived from 2
onsecutive questionnaires developed by an independent
teering committee (represented in the authors’ list) with
he aim of investigating the methods, efficacy, and safety of
A of AF as observed in a large number of electrophysiol-
gy (EP) laboratories worldwide between 1995 and 2002 (5)
first questionnaire) and between 2003 and 2006 (second
uestionnaire) (Online Appendix). In both questionnaires,
enters were asked to report the number of early (i.e., within
0 days from intervention) and late (i.e., after 30 days from,
ut as a consequence of, intervention) deaths and to provide
description of the sequence of precipitating events and
ltimate cause of death. The surveys were approved by the
nstitutional review board at Policlinico, San Donato.
Overall, questionnaires were sent to 546 EP centers (823
hysician contacts) worldwide. Centers were selected from
he following sources: the Heart Rhythm Society member
ist, the European Society of Cardiology member list, and
fficial lists of national working groups on arrhythmias in
ifferent countries of Europe; Asia; North, Central, and
outh America; Africa; and Oceania. Between November
001 and June 2002 for the first questionnaire, and between
arch and November 2006 for the second questionnaire,
elected addresses were contacted by fax, and contact was
e-enforced by means of e-mail in all cases. For addresses
ot responding after the first contact, a second contact was
ttempted 1 month later using the same modalities. Each
onresponder was telephoned to confirm the contact infor-
ation. All questionnaires were submitted under the as-
umption that the identity of physicians and institutions
ould remain anonymous. Completed questionnaires were
ent to an independent statistical center (Statistical Unit of
oliclinico, San Donato, Italy) for analysis. All data were
ntered into a database using Excel (Microsoft, Redmond,
ashington), and the statistical analysis was performed
sing the SPSS software (SPSS Inc., Chicago, Illinois).
Of the 546 identified EP centers, 39 were excluded
ecause they did not perform interventional EP, and 141
ecause they declared no active program for CA of AF. Of
ll interviews submitted to the remaining 366 centers
eligible centers), 162 were complete (i.e., more than 80% of
ll questions were answered with full disclosure of efficacy
nd safety data) (11), 99 were incomplete, and 105 were not
eturned. This yielded a response rate of 71%. Causes of
ncomplete interviews included omitted information about
fficacy in 64 centers and absence of a prospectively main-
ained database in 29 centers.
In order to investigate the contribution of center experi-
nce in determining the risk of intraprocedural or post- Trocedural death, the incidence
f death was compared in 3
roups selected according to the
umber of patients treated (i.e.,
ewer than 100 patients, between
00 and 250 patients, and more
han 250 patients). The contri-
ution of the type of CA tech-
ique in determining the risk of
ntraprocedural or post-procedural
eath was calculated by compar-
ng the incidence of death in
ubgroups of patients undergoing
ARTO-guided left atrial ablation versus Lasso-guided PV
solation. The former technique implied 3-D–assisted elec-
roanatomical reconstruction of the target ablation area (2),
hereas the latter technique referred to segmental PV
solation using a circular multipolar mapping catheter ad-
anced at the PVs, guiding energy delivery through an
blation catheter proximal to it under fluoroscopy guidance
3). The contribution of the type of catheter used in
etermining the risk of intraprocedural or periprocedural
eath was calculated by comparing the incidence of death in
ubgroups of patients receiving radiofrequency (RF) delivery
y means of a 4-mm–tip catheter versus an irrigated or
ooled-tip catheter. These ablation techniques and ablation
atheters were selected post hoc, as they were those most
requently used by centers participating in the surveys.
ubgroups were formed based on patients treated in centers
ith exclusive experience in the analyzed strategies.
tatistical analysis. Data are expressed as percentages for the
ominal variables, as medians for the ordinal variables, and as
eans for continuous variables. Discrete variables were com-
ared using the chi-square or Fisher exact test as appropriate.
value of p  0.05 was considered statistically significant.
esults
uring the time period covered by the questionnaires,
2,569 patients underwent 45,115 attempts at CA of AF
median procedures per center, 275; range 2 to 1,328).
able 1 reports the main characteristics of the 2 surveys.
hirty-one centers reported 32 deaths. A detailed list of the
ifferent causes of death is reported in Table 2. Twenty-five
eaths occurred within 30 days, and 7 deaths occurred later
han 30 days after the procedure. Among early deaths, 13
ccurred intraoperatively including 5 due to tamponade
eading to irreversible pump failure, 2 due to stroke, 1 due to
yocardial infarction leading to irreversible pump failure, 1
ue to extrapericardial PV perforation, 1 due to torsades de
ointes refractory to multiple attempts of electrical defibril-
ation and intravenous antiarrhythmic drug therapy (not
urther specified), 1 due to irreversible sudden respiratory
rrest, and 1 due to anaphylaxis secondary to intravenous
rothamine administration in the setting of tamponade.
Abbreviations
and Acronyms
AF  atrial fibrillation
CA  catheter ablation
EP  electrophysiology
PV  pulmonary vein
RF  radiofrequency
SV  supraventricular
TEE  transesophageal
echocardiographichirteen more early deaths occurred in the hours or days
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Fatalities in Catheter Ablation of AF May 12, 2009:1798–803ollowing the ablation procedures and included atrioesopha-
eal fistula in 5 patients, cardiac arrest secondary to anoxic
ncephalopathy in 2 patients experiencing intraoperative
amponade, massive pneumonia refractory to antibiotic
herapy in 2 patients, massive hemothorax from the site of
ubclavian puncture several hours after an uneventful pro-
edure in 1 patient, acute occlusion of both lateral PVs in 1
atient, cardiac arrest secondary to ischemic cerebral dam-
ge in 1 patient, and septicemia unrelated to PV stenosis or
trioesophageal fistula in 1 patient. Among late deaths, 5
ain Characteristics of the Present Survey
Table 1 Main Characteristics of the Present Survey
No. of centers reporting data on efficacy and safety 162
No. of centers reporting data on safety 262
No. of patients 32,569
No. of procedures 45,115
Male, % 61.9
Lower and upper age limit for entry, yrs 18–90
Proportion (%) of centers based on no. of procedures per year
20 35
21 to 50 28
51 to 100 24
100 13
Proportion (%) of centers with experience in one ablation technique
Lasso-guided 27
CARTO-guided 48
Other techniques 4
Combination 21
auses and Proportions of Death in 32,569 Patients From 162 Cen
Table 2 Causes and Proportions of Death in 32,569 Patients F
Cause of Death
Early death (within 30 days from procedure)
Tamponade with subsequent cardiac arrest
Atrioesophageal fistula
Peripheral embolism
Stroke
Myocardial infarction
Massive pneumonia
Extrapericardial pulmonary vein perforation
Irreversible torsades de pointes
Septicemia (3 weeks after procedure)
Sudden respiratory arrest
Acute pulmonary vein occlusion of both lateral veins
Hemothorax
Anaphylaxis
Late death (after 30 days from procedure)
Complications from prior perioperative events
Stroke
Tracheal compression from subclavian hematoma
Acute respiratory distress syndrome
Esophageal perforation from intraoperative TEE probe
Acutely precipitating events
Tamponade with subsequent cardiac arrest in prior stroke
Intracranial bleeding under oral anticoagulation therapy in prior strokeEE  transesophageal echocardiographic.ere due to complications from intraoperative or perioper-
tive early events including cardiac arrest secondary to stroke
n 2 patients, fatal tracheal compression from subclavian
ematoma in 1 patient receiving subclavian puncture at time
f procedure, acute respiratory distress syndrome possibly
elated to oral amiodarone therapy in 1 patient, and esoph-
geal perforation from an intraoperative transesophageal
chocardiographic probe in 1 patient. Two more late deaths
ere related to acutely precipitating events and included
amponade leading to irreversible pump failure occurring 50
ays after the procedure in 1 patient with post-operative
troke, and intracranial bleeding under oral anticoagulation
herapy in 1 patient with post-operative stroke. The inci-
ence of death according to the type of complication is
eported in Table 3.
Death rates did not significantly differ in centers with
100 overall performed procedures (0.11% in 1,765 pa-
ients undergoing 2,400 procedures in 93 centers), centers
ith 100 to 250 overall performed procedures (0.11% in
,100 patients undergoing 8,418 procedures in 37 centers),
nd in centers with 250 overall performed procedures
0.09% in 24,704 patients undergoing 37,250 procedures in
2 centers) (p  0.87). Similarly, no differences were found
n death rates between patients undergoing CARTO-
uided CA (0.18% in 4,665 patients undergoing 6,438
rocedures in 21 centers) and patients undergoing Lasso-
uided CA (0.08% in 2,385 patients undergoing 3,387
rocedures in 17 centers) (p 0.51). Finally, death rates did
62 Centers
traoperative
(n)
Post-Operative
(n)
Total
(n)
Proportion
(%)
5 2 7 21.8
0 5 5 15.6
2 1 3 9.4
1 0 1 3.1
0 2 2 6.3
1 0 1 3.1
1 0 1 3.1
0 1 1 3.1
1 0 1 3.1
0 1 1 3.1
0 1 1 3.1
1 0 1 3.1
2 6.3
1 3.1
1 3.1
1 3.1
1 3.1
1 3.1ters
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May 12, 2009:1798–803 Fatalities in Catheter Ablation of AFot significantly differ between patients undergoing CA
ith the use of a 4-mm–tip catheter electrode (0.19% in
3,470 patients undergoing 4,771 procedures in 21 centers)
nd patients undergoing CA with the use of an irrigated/
ooled-tip electrode (0.23% in 5,271 patients undergoing
,327 procedures in 9,413 centers) (p  0.19). Centers
eporting death events did not differ with other centers with
egard to efficacy and safety rates (p  0.78 and p  0.82,
espectively).
iscussion
eath is an uncommon complication associated with CA
echniques. In previous surveys conducted in patients un-
ergoing ablation, death was reported as a procedure-related
omplication in 0.11% to 0.30% of patients with regular
upraventricular (SV) tachycardias (12,13) and 0.31% in
atients with ventricular tachycardias (13). In these surveys,
auses of death were either incompletely reported or not
eported. Systematic evaluation of causes is impaired by
mall numbers even in multicenter studies with large pop-
lations of investigated patients (12,13).
Catheter ablation for curative treatment of AF is associ-
ted with unique considerations that may precipitate fatal
omplications. These include transseptal puncture, pro-
onged catheter manipulation in the left atrium, and large
oses of cumulative RF energy delivered in the left atrium in
he context of a high level of systemic anticoagulation. In a
ecent survey, transseptal catheterization was shown to be a
ause of death in 0.2% of procedures (14).
In the present study, we found that the incidence of death
ssociated with CA of AF is 1 of every 1,000 patients.
ardiac tamponade was the most frequent fatal complica-
ion leading to intraoperative irreversible pump failure
econdary to myocardial hypoperfusion, post-operative early
Fatality Rates According to Type of Complicatio
Table 3 Fatality Rates According to Type of
Complication
Tamponade
Atrioesophageal fistula
Massive pneumonia
Peripheral embolism
Stroke
Myocardial infarction
Torsades de pointes
Septicemia (3 weeks after procedure)
Sudden respiratory arrest
Acute pulmonary vein occlusion of both lateral veins
Internal bleeding (includes hemothorax, subclavian hemato
extrapericardial pulmonary vein perforation)
Anaphylaxis
Acute respiratory distress syndrome
Esophageal perforation from intraoperative TEE probe
Intracranial bleeding under oral anticoagulation therapy in p
TEE  transesophageal echocardiographic.ardiac arrest, or sudden pericardial bleeding occurring 50 days after the procedure. Late tamponade represents an
nreported complication. Development of atrioesophageal
stulas was the second most frequent cause of death. This
omplication has been reported to present between 10 and
6 days after the ablation procedure, and to be fatal in the
ajority of patients (7–10). Causes of death in these
atients include cerebral air embolism, massive gastrointes-
inal bleeding, and septic shock (15). Ischemic brain or
yocardial damage was the third most frequent cause of
eath. Modes of death associated with this complication
ncluded intraprocedural acute myocardial infarction as well
s intra- or post-procedural stroke. The fourth most com-
on cause of death was extrapericardial bleeding mostly due
o subclavian or PV perforation. Another cause of death
ncluded massive pneumonia refractory to antibiotic ther-
py. Conditions such as torsades de pointes, sudden respi-
atory arrest, and acute respiratory distress syndrome appear
o be unspecific causes of death; it is likely that they
epresented the final event of unrecognized causes ulti-
ately leading to a fatal outcome. Some of the complica-
ions leading to death in this series, such as bleeding from
he subclavian access site, are clearly unrelated to CA of AF
nd could be observed for EP procedures requiring the same
ccess; however, it is possible that the anticoagulation
trategies operated for the purpose of this specific procedure
ay have influenced the outcome.
The larger prevalence of causes of death such as tampon-
de, peripheral embolism, and internal bleeding reflects a
igher frequency in these complications, but their probabil-
ty to cause death once they have developed is smaller as
ompared with more occasional complications such as
trio-esophageal fistula, septicemia, and acute respiratory
istress syndrome.
Center experience did not appear to influence the inci-
plication
Death/Overall Events
(n)
Rate
(%)
7/331 2.3
5/7 71.4
2/2 100.0
3/59 5.1
1/3 33.3
1/1 100.0
1/3 33.3
1/1 100.0
1/6 16.7
d 3/21 14.3
1/6 16.7
1/1 100.0
1/1 100.0
roke 1/4 25.0n
Com
ma, an
rior stence of death. CARTO-guided left atrial ablation and
L
e
i
v
t
t
p
o
n
i
a
t
2
s
s
w
r
r
S
o
d
c
a
p
d
s
d
g
t
s
e
d
p
r
i
t
m
e
p
m
l
a
n
i
c
m
w
e
r
t
c
t
q
a
S
s
H
t
a
r
d
r
r
p
fi
m
C
D
u
p
d
i
s
e
t
n
d
A
T
d
M
G
m
R
A
n
E
R
1802 Cappato et al. JACC Vol. 53, No. 19, 2009
Fatalities in Catheter Ablation of AF May 12, 2009:1798–803asso-guided PV isolation were not associated with differ-
nt risks of death. A 2.5-fold increase in death rate observed
n patients undergoing irrigated or cooled-tip ablation
ersus 4-mm–tip ablation raises some concern with regard
o the potential harm of the first type of catheter, although
his difference did not reach statistical significance. Careful
rospective monitoring is advised to exclude a greater degree
f harm with use of more powerful ablation catheters.
The incidence of perioperative death in this survey did
ot differ from the incidence of perioperative death observed
n catheter ablation of regular SV tachycardias as previously
ssessed with a similar retrospective method (12). Although
he comparison is limited by the time interval between the
surveys, which may have improved the performance
tandards and experience of investigators, this observation
uggests that procedural challenges exclusively associated
ith CA of AF may not be associated with an additional
isk of death when compared with catheter ablation of
egular SV tachyarrhythmias.
tudy limitations. First, this survey reflects the experience
f those centers that volunteered to respond to our call and
oes not correspond to the experience of all contacted
enters. Therefore, the incidence of perioperative mortality
nd the distribution of causes of death observed in the entire
opulation of patients undergoing CA of AF may be
ifferent from that observed in the present study. In a recent
tudy that also used an anonymous volunteer method for
ata collection (7), at least 4 more cases of fatal atrioesopha-
eal fistula were reported, which were not made available to
he present surveys. Second, the retrospective nature of the
tudy may lead to underestimation of the true incidence of
vents. Prior studies in CA of regular SV tachycardias have
ocumented a 3-fold increase in the mortality rates of
rospective surveys (13) when compared with mortality
ates of retrospective studies (12). The risk of a higher
ncidence of procedure-related death and other complica-
ions when collecting data according to a prospective
ethod needs to be highlighted, particularly when consid-
ring that about one-third of patients require multiple
rocedures for curative treatment. Third, systematic assess-
ent of predictors of perioperative death was limited by the
ack of individual patient data in the study database as well
s by the very low incidence of fatal events and their variable
ature. This limit is reflected in the inability to gather
ndividual data on the victims’ ages, sex, type of AF, or
omorbidities according to a systematic data collection
ode. Also, the subgroup analyses performed in this study
ere based on an arbitrary selection of identifiable param-
ters or cutoff limits made available by the specific questions
aised by the questionnaires, and excluded investigation on
he role of intermediate conditions such as those observed in
enters experiencing a variety of techniques or catheters
hroughout their experience. It is possible that designing
uestionnaires with more-detailed questions or selecting
lternative cutoff values may have led to different results.
imilarly, different results may have been obtained using theame questionnaires according to a prospective design.
owever, it should be noted that the very low incidence of
he target event evaluated in this study makes it unlikely that
ny investigated clinical and instrumental parameter would
esult in being a significant predictor of outcome. Finally,
escription of precipitating causes reflects the clinical accu-
acy of responding physicians. Although the vast majority of
eported causes appears obvious, some (e.g., torsades de
ointes and sudden respiratory arrest) likely represent the
nal event of unspecified or unrecognized conditions pri-
arily responsible for a fatal outcome.
onclusions
espite these limitations, the present study provides an
nprecedented view on the causes and incidence of death in
atients undergoing CA of AF, which may be of help in
esigning more appropriate and efficient EP settings for
ncreasing current standards of procedural safety, planning
tart programs in EP centers with limited facilities or
xperience, delivering recommendations by regulatory au-
horities, and developing safer technologies. Finally, aware-
ess about this complication needs to be considered during
ecision making with patients.
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